Oral Bisphosphonates Reduce Endometrial Cancer Risk

Share this content:
Oral bisphosphonates may greatly reduce the risk of endometrial cancer.
Oral bisphosphonates may greatly reduce the risk of endometrial cancer.

Oral bisphosphonates may greatly reduce the risk of endometrial cancer, according to a recent study published online ahead of print in the Journal of Clinical Oncology.

Polly Newcomb, PhD, MPH, of the Fred Hutchinson Cancer Research Center and colleagues conducted a large prospective cohort of 89,918 postmenopausal women who participated in the Women's Health Initiative.

RELATED: Soy, Isoflavone Intake Not Linked to Endometrial Cancer

“Several studies have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies,” the authors noted.

Detailed interviews were conducted with patients at baseline, with bisphosphonate data at baseline and over follow-up. With a median follow-up of 12.5 years, 1,123 women were diagnosed with endometrial cancer.

They found that bisphosphonate use was associated with a reduced risk of endometrial cancer, with no interactions based on age, BMI, or indication for use.

Reference

  1. Newcomb, Polly A., et al. "Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer." Journal of Clinical Oncology. doi: 10.1200/JCO.2014.58.6842. [epub ahead of print]. February 23, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters